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Introduction
The National Cholesterol Education Program Adult
Treatment Panel (NCEP ATP) III guidelines recom-
mend a low-density lipoprotein cholesterol (LDL-C)
goal < 100 mg ⁄dl (2.59 mmol ⁄ l) for high-risk
patients (those with clinical cardiovascular disease,
diabetes, or 10-year coronary heart disease [CHD]
risk > 20%) and suggest an optional LDL-C goal
< 70 mg ⁄ dl (1.81 mmol ⁄ l) for those at the highest
risk, including those with established cardiovascular
disease plus additional high-risk characteristics such
as diabetes mellitus, multiple cardiovascular risk fac-
tors, and ⁄or metabolic syndrome (1). In order to
achieve LDL-C < 100 mg ⁄dl (2.59 mmol ⁄ l) the
majority of moderately high- and high-risk patients
will need high-dose statin or a combination of statin
and another lipid-lowering agent [reviewed in Ref.
(2)]. Furthermore, in order to achieve an
LDL-C < 70 mg ⁄dl (1.81 mmol ⁄ l), almost all very
high-risk patients will need high-dose statin or a com-
bination of statin and another lipid-lowering agent
[reviewed in Ref. (2)]. Advantages of using combina-
tion therapy include greater efficacy through differing
mechanisms of action, lower doses of individual
drugs, and potential amelioration of side effects expe-
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SUMMARY
Aims: The aim of this analysis was to assess the overall safety and tolerability
profiles of various statins + ezetimibe vs. statin monotherapy and to explore toler-
ability in sub-populations grouped by age, race, and sex. Methods: Study-level
data were combined from 27 double-blind, placebo-controlled or active-comparator
trials that randomized adult hypercholesterolemic patients to statin or statin + eze-
timibe for 6–24 weeks. In the full cohort, % patients with AEs within treatment
groups (statin: N = 10,517; statin + ezetimibe: N = 11,714) was assessed by
logistic regression with terms for first- ⁄ second-line therapy (first line = drug-naı¨ve
or rendered drug-naı¨ve by washout at study entry; second line = ongoing statin at
study entry or statin run-in), trial within first- ⁄ second-line therapy, and treatment.
The same model was fitted for age (< 65, ‡ 65 years), sex, race (white, black,
other) and first- ⁄ second-line subgroups with additional terms for subgroup and
subgroup-by-treatment interaction. Results: In the full cohort, the only significant
difference between treatments was consecutive AST or ALT elevations ‡ 3 · upper
limit of normal (ULN) (statin: 0.35%, statin + ezetimibe: 0.56%; p = 0.017). Sig-
nificantly more subjects reported ‡ 1 AE; drug-related, hepatitis-related and gastro-
intestinal-related AEs; and CK elevations ‡ 10 · ULN (all p £ 0.008) in first-line
vs. second-line therapy studies with both treatments. AEs were generally similar
between treatments in subgroups, and similar rates of AEs were reported within
age and race subgroups; however, women reported generally higher AE rates.
Conclusions: In conclusion, in second-line studies, ongoing statin treatment at
study entry likely screened out participants for previous statin-related AEs and tol-
erability issues. These results describe the safety profiles of widely used lipid-lower-
ing therapies and encourage their appropriate and judicious use in certain
subpopulations.
What’s known
The general safety and tolerability profiles of statin
monotherapy and statin + ezetimibe combination
therapy have been established. Comparable safety
and tolerability profiles have been reported in
subgroups by sex, race and age, although these
secondary analyses have not been powered to
assess statistical differences. Some cases of
myopathy and rare cases of rhabdomyolysis have
been reported during treatment with statins and
ezetimibe.
What’s new
The general safety and tolerability profiles of statin
monotherapy and statin + ezetimibe combination
therapy were confirmed. Irrespective of treatment
group, generally higher rates of AEs were reported
in women vs. men, and generally similar rates of
AEs were reported between races and between age
groups. More AEs were reported in first-line studies
vs. second-line studies. The occurrence of myopathy
was low and did not differ between treatments or
any of the subgroups studied.
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rienced with high doses of single agents. The potential
disadvantages of combination therapy include drug
interactions, increased number of pills, greater cost,
and additive side effects. Moreover, data on clinical
outcomes with combination therapy are limited.
The general safety and tolerability profiles of statin
monotherapy and statin + ezetimibe combination
therapy have been established in multiple clinical tri-
als [reviewed in Refs (3,4)]. Cases of myopathy and
rare cases of rhabdomyolysis have been reported dur-
ing treatment with statins (5) and ezetimibe (6).
With statins, these cases can occur at any dose level,
but the risks increase at the higher doses and with
certain concomitant medications (7–11). Clinical tri-
als that have assessed lipid-lowering treatments are
generally not powered to identify small between-
treatment differences in safety and tolerability or rare
adverse experiences. Moreover, conclusions drawn
about differences in subpopulations, such as those
assessed by age, race and sex, have been limited due
to group size. The objective of this analysis was to
assess the overall safety and tolerability profiles of
various statins + ezetimibe vs. statin monotherapy
and to explore tolerability in sub-populations
grouped by age, race, and sex in a population of over
22,000 patients using pooled data combined from
previously published trials.
Methods
In this analysis, study-level data were combined from
27 double-blind, placebo-controlled or active-
comparator studies conducted between 1999 and
2008 by Merck Research Laboratories. In these studies
adult hypercholesterolemic patients were randomized
to statin or statin + ezetimibe for 6–24 weeks
(Table 1) with a mean follow up duration of 9 weeks.
Included studies were relatively short-term, lipid-low-
ering trials. Studies with cross-over design, extension
studies, studies still ongoing, imaging studies, studies
in which ezetimibe was used as monotherapy or in
combination with other non-statin lipid-lowering
drugs (e.g., fenofibrate, niacin), adolescent or pediat-
ric patient studies, and studies focusing on patients
with sitosterolemia, homozygous familial hypercho-
lesterolemia, aortic stenosis, or chronic kidney disease
were not included in these analyses.
Specific inclusion criteria for the individual studies
have been previously published (see citations in
Table 1). Since guidelines have changed over time,
there was no single lipid entry criterion that applied
to all studies. Generally, a patient was considered
hypercholesterolemic if LDL-C levels were above
guideline-recommended levels according to risk. The
range of baseline LDL-C inclusion levels in the stud-
ies was between 70 mg ⁄dl (1.81 mmol ⁄ l) to
250 mg ⁄dl (6.47 mmol ⁄ l; Table 1).
Thirteen studies evaluated first-line therapy, which
included subjects who were drug-naı¨ve or rendered
drug-naı¨ve by wash-out at study start, and random-
ized patients to receive double-blind ezetimibe ⁄ statin
[ezetimibe ⁄ simvastatin combination tablet (10 ⁄ 10,
10 ⁄ 20, 10 ⁄ 40, or 10 ⁄ 80 mg) or ezetimibe 10 mg co-
administered with: simvastatin 10, 20, 40, or 80 mg;
lovastatin 10, 20, or 40 mg; pravastatin 10, 20, or
40 mg or atorvastatin 10, 20, 40 or 80 mg] or statin
alone (simvastatin 10, 20, 40, and 80 mg; lovastatin
10, 20, and 40 mg; pravastatin 10, 20, and 40 mg;
atorvastatin 10, 20, 40, and 80 mg or rosuvastatin 10,
20, or 40 mg) for up to 12 weeks. There were 14 stud-
ies that evaluated second-line therapy, which included
subjects who were previously on statins or receiving
statins during run-in. In the add-on therapy studies
(11 studies), statin-treated patients were randomized
to receive double-blind placebo or ezetimibe 10 mg
administered in combination with their ongoing, pre-
viously prescribed, open-label statin, which may have
been doubled in some studies (simvastatin 10, 20, 40,
or 80 mg; lovastatin 10, 20, or 40 mg; pravastatin 10,
20, or 40 mg; fluvastatin 20, 40, 80, or 160 mg; ator-
vastatin 10, 20, 40, or 80 mg or cerivastatin 0.2, 0.3,
0.4, or 0.8 mg) for up to 8 weeks. In ‘‘switch-therapy’’
studies (3 studies), statin-treated patients were
switched from their ongoing, previously prescribed,
open-label statin (simvastatin 10, 20, or 40 mg; lova-
statin 10 or 20 mg; pravastatin 10 or 20 mg; fluvasta-
tin 10 or 40 mg; atorvastatin 10, 20, or 40 mg or
rosuvastatin 5 mg) to receive double-blind ezetim-
ibe ⁄ statin (ezetimibe ⁄ simvastatin combination tablet
10 ⁄ 20 or 10 ⁄ 40 mg) or statin alone (simvastatin 20,
40, or 80 mg; lovastatin 20 or 40 mg; pravastatin 20
or 40 mg; fluvastatin 20 or 80 mg; atorvastatin 20, 40,
or 80 mg or rosuvastatin 10 mg) for up to 24 weeks.
Specific statin type and dose were matched between
comparison groups in some trials, and in other trials,
common-use comparisons were made (i.e., doses were
compared that would frequently be used in a clinical
setting, e.g. starting dose vs. starting dose, next higher
dose vs. next-higher dose; Table 1).
Adverse experiences (AEs) were summarized by
system organ class and specific adverse experience
term. Prespecified safety parameters included alanine
aminotransferase (ALT) and ⁄or aspartate amino-
transferase (AST) consecutive elevations ‡ 3 · upper
limit of normal (ULN); creatine kinase (CK) eleva-
tions ‡ 10 · ULN; CK elevations ‡ 10 · ULN with
muscle symptoms (myopathy), and myopathy with
associated evidence of renal damage (rhabdomyoly-
sis). Special AEs of interest included hepatitis-
related, gallbladder-related, gastrointestinal-related,
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Table 1 Characteristics of studies included in the combined analyses
Protocol
number
(citation) Treatment
Study
duration
n of subjects
who took statin
(N = 10,387)
n of subjects
who took statin + EZ
(N = 11,891)
Inclusion criteria
Min LDL-C Max LDL-C
005 (24) EZ, PBO
EZ + S 20, 40, 80
S 20, 40, 80
12 weeks 229 539 145 mg ⁄ dl (3.75 mmol ⁄ l) 250 mg ⁄ dl (6.47 mmol ⁄ l)
011 (25) EZ, PBO
S 10, 20, 40, 80
EZ + S 10, 20, 40, 80
12 weeks 263 274 145 mg ⁄ dl (3.75 mmol ⁄ l) 250 mg ⁄ dl (6.47 mmol ⁄ l)
021 (26) EZ + S 20
S 40
24 weeks 110 104 101 mg ⁄ dl (2.62 mmol ⁄ l) Not specified
023 (27) S 20
EZ + S 20, 40, 80
23 weeks 253 457 130 mg ⁄ dl (3.37 mmol ⁄ l) Not specified
025 (28) A 10–80
EZ ⁄ S 10–80
24 weeks 262 526 Not at LDL-C goal as defined by NCEP ATP III
030 (29) EZ + A 10, 20, 40
A 10, 20, 40, 80
14 weeks 316 305 130 mg ⁄ dl (3.37 mmol ⁄ l) Not specified
038 (30) EZ, PBO
EZ ⁄ S 10, 20, 40, 80
S 10, 20, 40, 80
12 weeks 622 609 145 mg ⁄ dl (3.75 mmol ⁄ l) 250 mg ⁄ dl (6.47 mmol ⁄ l)
040 (31) EZ + ongoing statin
Ongoing statin
6 weeks 1009 2009 Not at LDL-C goal as defined by NCEP ATP III
051 (32) EZ ⁄ S 20, 40, 80
A 10 20, 40, 80
6 weeks 947 948 Not at LDL-C goal as defined by NCEP ATP III
058 (33) EZ ⁄ S 20, 40, 80
R 10, 20, 40
6 weeks 1477 1474 145 mg ⁄ dl (3.75 mmol ⁄ l) 250 mg ⁄ dl (6.47 mmol ⁄ l)
077 (34) EZ ⁄ S 20, 40
A 10, 20, 40
6 weeks 732 494 100 mg ⁄ dl (2.59 mmol ⁄ l) Not specified
079 (35) EZ + A 20
A 40
6 weeks 98 96 100 mg ⁄ dl (2.59 mmol ⁄ l) 160 mg ⁄ dl (4.14 mmol ⁄ l)
090 (36) EZ + A 40
A 80
6 weeks 289 286 70 mg ⁄ dl (1.81 mmol ⁄ l) 160 mg ⁄ dl (4.14 mmol ⁄ l)
107 (37) EZ ⁄ S 20, 40
A 10, 20, 40
6 weeks 678 450 70 mg ⁄ dl (1.81 mmol ⁄ l)
100 mg ⁄ dl (2.59 mmol ⁄ l)
Not specified
112 (38) EZ + A 10
A 20 ⁄ 40
6 weeks 525 526 70 mg ⁄ dl (1.81 mmol ⁄ l) 160 mg ⁄ dl (4.14 mmol ⁄ l)
679 (39) EZ, PBO
L 10, 20, 40
EZ + L 10, 20, 40
12 weeks 220 192 145 mg ⁄ dl (3.75 mmol ⁄ l) 250 mg ⁄ dl (6.47 mmol ⁄ l)
691 (40) EZ, PBO
P 10, 20, 40
EZ + P 10, 20, 40
12 weeks 205 204 145 mg ⁄ dl (3.75 mmol ⁄ l) 250 mg ⁄ dl (6.47 mmol ⁄ l)
692 (41) EZ, PBO
A 10, 20, 40, 80
EZ + A 10, 20, 40, 80
12 weeks 248 255 145 mg ⁄ dl (3.75 mmol ⁄ l) 250 mg ⁄ dl (6.47 mmol ⁄ l)
700 (42) EZ
S 20, 40
14 weeks 34 66 130 mg ⁄ dl (3.37 mmol ⁄ l) Not specified
801 (43) EZ + S 10, 20
S 10, 20
6 weeks 210 208 101 mg ⁄ dl (2.62 mmol ⁄ l) 160 mg ⁄ dl (4.14 mmol ⁄ l)
802 (44) EZ + S 10, 20
S 10, 20
6 weeks 191 181 101 mg ⁄ dl (2.62 mmol ⁄ l) 160 mg ⁄ dl (4.14 mmol ⁄ l)
803 ⁄ 804 (45) EZ + A 10, 20
A 10, 20
6 weeks 230 220 101 mg ⁄ dl (2.62 mmol ⁄ l) 160 mg ⁄ dl (4.14 mmol ⁄ l)
806 (46) EZ ⁄ S 20
A 20
6 weeks 214 221 100 mg ⁄ dl (2.62 mmol ⁄ l) 160 mg ⁄ dl (4.14 mmol ⁄ l)
807 (47) ES 20, 40
A 20
6 weeks 219 442 101 mg ⁄ dl (2.62 mmol ⁄ l) 160 mg ⁄ dl (4.14 mmol ⁄ l)
809 (48) EZ ⁄ S 20
R 10
6 weeks 293 302 100 mg ⁄ dl (2.59 mmol ⁄ l) 160 mg ⁄ dl (4.14 mmol ⁄ l)
2173 ⁄ 2246 (49) EZ + ongoing statin
Ongoing statin
8 weeks 390 379 Not at LDL-C goal as defined by NCEP ATP III
3377 (50) EZ + S 20
S 20
12 weeks 123 124 145 mg ⁄ dl (3.75 mmol ⁄ l) 250 mg ⁄ dl (6.47 mmol ⁄ l)
A, atorvastatin; EZ, ezetimibe; L, lovastatin; LDL-C, low-density lipoprotein cholesterol; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; P, pravastatin; R, rosuvastatin; S, simvastatin.
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Table 2 Baseline characteristics for ITT population and subgroups included in analyses
ITT population
Parameter Statin
(N = 10,308)
Statin ⁄ EZ
(N = 11,486)
Total
(N = 21,794)
Male, n (%) 5279 (51.2) 6016 (52.4) 11,295 (51.8)
Female, n (%) 5029 (48.8) 5470 (47.6) 10,499 (48.2)
Mean age, years (SD) 59.2 (11.3) 59.9 (11.1) 59.6 (11.2)
< 65 years, n (%) 6682 (64.8) 7250 (63.1) 13,932 (63.9)
‡ 65 years, n (%) 3626 (35.2) 4236 (36.9) 5989 (36.1)
Caucasian, n (%) 8690 (84.3) 9706 (84.5) 18,396 (84.4)
Non-Caucasian, n (%) 1618 (15.7) 1780 (15.5) 3398 (15.6)
CHD, n (%) 3310 (32.1) 4115 (35.9) 7425 (34.1)
Diabetes mellitus, n (%) 3082 (29.9) 3459 (30.1) 6541 (30.0)
Metabolic syndrome, n (%) 4233 (50.7) 4518 (49.7) 8751 (50.1)
First-line, n (%) 6257 (60.7) 6241 (54.3) 12,498 (57.3)
Second-line, n (%) 4051 (39.3) 5245 (45.7) 9296 (42.7)
BMI ‡ 30 kg ⁄m2, n (%) 4138 (40.8) 4537 (40.1) 8675 (40.4)
BMI (kg ⁄m2) (n = 10,143) (n = 11,315) (n = 21,458)
Mean (SD) 29.8 (5.9) 29.7 (5.8) 29.8 (5.8)
Men Women
Statin
(n = 5279)
Statin ⁄ EZ
(n = 6016)
Statin
(n = 5029)
Statin ⁄ EZ
(n = 5470)
Mean age, years (SD) 58.4 (11.2) 59.2 (11.1) 60.0 (11.2) 60.7 (11.0)
< 65 years, n (%) 3556 (67.4) 3909 (65.0) 3126 (62.2) 3341 (61.1)
‡ 65 years, n (%) 1723 (32.6) 2107 (35.0) 1903 (37.8) 2129 (38.9)
Caucasian, n (%) 4549 (86.2) 5187 (86.2) 4141 (82.3) 4519 (82.6)
Non-Caucasian, n (%) 730 (13.8) 829 (13.8) 888 (17.7) 951 (17.4)
CHD, n (%) 2129 (40.3) 2614 (43.5) 1181 (23.5) 1501 (27.5)
Diabetes mellitus, n (%) 1491 (28.2) 1732 (28.8) 1591 (31.6) 1727 (31.6)
Metabolic syndrome, n (%) 1912 (46.5) 2112 (45.8) 2321 (54.7) 2406 (53.6)
First-line, n (%) 3008 (57.0) 3081 (51.2) 3249 (64.6) 3160 (57.8)
Second-line, n (%) 2271 (43.0) 2935 (48.8) 1780 (35.4) 2310 (42.2)
BMI ‡ 30 kg ⁄m2, n (%) 1916 (36.8) 2206 (37.2) 2222 (45.0) 2331 (43.3)
BMI (kg ⁄m2) (n = 5201) (n = 5931) (n = 4942) (n = 5384)
Mean (SD) 29.3 (5.1) 29.4 (5.1) 30.3 (6.5) 30.1 (6.5)
< 65 years ‡ 65 years
Statin
(n = 6682)
Statin ⁄ EZ
(n = 7250)
Statin
(n = 3626)
Statin ⁄ EZ
(n = 4236)
Mean age, years (SD) 52.8 (8.3) 53.3 (7.9) 70.9 (4.5) 71.3 (4.8)
Male, n (%) 3556 (53.2) 3909 (53.9) 1723 (47.5) 2107 (49.7)
Female, n (%) 3126 (46.8) 3341 (46.1) 1903 (52.5) 2129 (50.3)
Caucasian, n (%) 5451 (81.6) 5962 (82.2) 3239 (89.3) 3744 (88.4)
Non-Caucasian, n (%) 1231 (18.4) 1288 (17.8) 387 (10.7) 492 (11.6)
CHD, n (%) 1842 (27.6) 2189 (30.2) 1468 (40.5) 1926 (45.5)
Diabetes mellitus, n (%) 1897 (28.4) 2077 (28.6) 1185 (32.7) 1382 (32.6)
Metabolic syndrome, n (%) 2660 (49.0) 2734 (47.3) 1573 (53.8) 1784 (53.8)
First-line, n (%) 4555 (68.2) 4465 (61.6) 1702 (46.9) 1776 (41.9)
Second-line, n (%) 2127 (31.8) 2785 (38.4) 1924 (53.1) 2460 (58.1)
BMI ‡ 30 kg ⁄m2, n (%) 2910 (44.4) 3106 (43.6) 1228 (34.2) 1431 (34.1)
BMI (kg ⁄m2) (n = 6553) (n = 7124) (n = 3590) (n = 4191)
Mean (SD) 30.3 (6.2) 30.2 (6.1) 28.9 (5.1) 28.9 (5.1)
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and allergic reaction or rash-related (see specific
terms in footnote of Table 3). Safety populations
were defined based on their definitions at the time
of each individual study.
Laboratory AEs were analyzed in patients who had
‡ 1 post-baseline assessment; and special AEs of
interest were analyzed in All Patients as Treated
(APaT). In the full cohort, the percentage of patients
with AEs within treatment groups was assessed by a
logistic regression model with terms for first-line ⁄ sec-
ond-line therapy (statin-naı¨ve or rendered statin-
naı¨ve by washout ⁄ongoing statin at study entry), trial
within first- ⁄ second-line therapy, and treatment. The
same model was fitted for age (< 65, ‡ 65 years), sex
(male, female), race (white, black, other) and first-
line ⁄ second-line subgroups with additional terms for
subgroup and subgroup-by-treatment interaction. For
rare AEs (those with a rate < 1% for both statin and
statin plus ezetimibe treatments), the data were ana-
lyzed by a Poisson regression model. Due to the pau-
city of data, the trial within first- ⁄ second-line term
coefficient could not be estimated in the Poisson
regression model and was therefore excluded. For the
full cohort, a sensitivity analysis was performed by
way of risk difference using a logistic mixed model
and Miettinen & Nurminen method with ‘effective
sample size’. The logistic mixed model included terms
for first- ⁄ second-line study, treatment, and random
effect for study.
Results
There were 10,542 patients randomized to the statin
monotherapy groups and 11,746 subjects randomized
Table 2 (Continued)
White Black Other
Statin
(n = 8690)
Statin ⁄ EZ
(n = 9706)
Statin
(n = 722)
Statin ⁄ EZ
(n = 813)
Statin
(n = 896)
Statin ⁄ EZ
(n = 967)
Mean age, years (SD) 59.7 (11.2) 60.3 (11.0) 56.0 (11.1) 57.7 (11.1) 56.4 (11.3) 57.3 (11.4)
< 65 years, n (%) 5451 (62.7) 5962 (61.4) 560 (77.6) 589 (72.4) 671 (74.9) 699 (72.3)
‡ 65 years, n (%) 3239 (37.3) 3744 (38.6) 162 (22.4) 224 (27.6) 225 (25.1) 268 (27.7)
Male, n (%) 4549 (52.3) 5187 (53.4) 303 (42.0) 319 (39.2) 427 (47.7) 510 (52.7)
Female, n (%) 4141 (47.7) 4519 (46.6) 419 (58.0) 494 (60.8) 469 (52.3) 457 (47.3)
CHD, n (%) 2894 (33.3) 3586 (37.0) 153 (21.2) 178 (22.0) 263 (29.4) 351 (36.3)
Diabetes mellitus, n (%) 2407 (27.7) 2631 (27.1) 285 (39.5) 377 (46.4) 390 (43.5) 451 (46.6)
Metabolic syndrome, n (%) 3532 (49.8) 3805 (49.0) 293 (53.9) 343 (56.7) 408 (56.4) 370 (50.8)
First-line, n (%) 5138 (59.1) 5183 (53.4) 527 (73.0) 523 (64.3) 592 (66.1) 535 (55.3)
Second-line, n (%) 3552 (40.9) 4523 (46.6) 195 (27.0) 290 (35.7) 304 (33.9) 432 (44.7)
BMI ‡ 30 kg ⁄m2, n (%) 3412 (39.9) 3756 (39.3) 407 (57.2) 482 (60.0) 319 (36.0) 299 (31.3)
BMI (kg ⁄m2) (n = 8546) (n = 9557) (n = 712) (n = 804) (n = 885) (n = 954)
Mean (SD) 29.7 (5.8) 29.6 (5.7) 32.2 (6.9) 32.4 (6.3) 29.0 (5.5) 28.4 (5.5)
First-line Second-line
Statin
(n = 6257)
Statin ⁄ EZ
(n = 6241)
Statin
(n = 4051)
Statin ⁄ EZ
(n = 5245)
Mean age, years (SD) 57.3 (10.9) 57.9 (10.7) 62.1 (11.2) 62.2 (11.1)
< 65 years, n (%) 4555 (72.8) 4465 (71.5) 2127 (52.5) 2785 (53.1)
‡ 65 years, n (%) 1702 (27.2) 1776 (28.5) 1924 (47.5) 2460 (46.9)
Male, n (%) 3008 (48.1) 3081 (49.4) 2271 (56.1) 2935 (56.0)
Female, n (%) 3249 (51.9) 3160 (50.6) 1780 (43.9) 2310 (44.0)
Caucasian, n (%) 5138 (82.1) 5183 (83.0) 3552 (87.7) 4523 (86.2)
Non-Caucasian, n (%) 1119 (17.9) 1058 (17.0) 499 (12.3) 722 (13.8)
CHD, n (%) 1019 (16.3) 1194 (19.1) 2291 (56.6) 2921 (55.8)
Diabetes mellitus, n (%) 1751 (28.0) 1569 (25.1) 1331 (32.9) 1890 (36.0)
Metabolic syndrome, n (%) 1364 (53.8) 1938 (55.5) 2869 (49.3) 2580 (46.0)
BMI ‡ 30 kg ⁄m2, n (%) 2685 (43.9) 2538 (41.6) 1453 (36.0) 1999 (38.3)
BMI (kg ⁄m2) (n = 6114) (n = 6103) (n = 4029) (n = 5212)
Mean (SD) 30.2 (6.1) 29.9 (5.9) 29.2 (5.5) 29.5 (5.7)
BMI, body mass index; CHD, coronary heart disease; EZ, ezetimibe; SD, standard deviation.
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to the statin + ezetimibe combination groups within
the studies included. A total of 22,278 patients
received at least one dose of study drug and were
included in the safety analysis (Table 1).
Baseline characteristics
Baseline characteristics were generally similar between
treatment groups in the full cohort (Table 2). The
majority of the intent-to-treat (ITT) population was
Caucasian and the mean age (± standard deviation)
was 60 ± 11 years with a mean body mass index
(BMI) of 29.8 kg ⁄m2. Half of subjects (50.1%) had
metabolic syndrome, and approximately 1 ⁄ 3 of sub-
jects had CHD (34%) or diabetes mellitus (30%). At
baseline, 57% of subjects were treated as first-line,
and these subjects received statin monotherapy more
often than receiving combination statin ⁄ ezetimibe
(61% vs. 54%).
In the subgroups that were compared (Table 2), a
smaller proportion of women had CHD compared
Table 3 Summary of safety data in the full cohort
Statin Statin ⁄ EZ p-value for treatment
AE Summary, n (%) (N = 10,517) (N = 11,714)
‡ 1 AE 3455 (32.85) 3717 (31.73) 0.547
Drug-related* AE 833 (7.92) 961 (8.20) 0.163
Serious AEs (SAEs) 145 (1.38) 187 (1.60) 0.202
Drug-related* SAEs 6 (0.06) 13 (0.11) 0.148
Death 5 (0.05) 7 (0.06) 0.700
Discontinuations
Due to an AE 219 (2.08) 263 (2.25) 0.337
Due to drug-related* AE 136 (1.29) 177 (1.51) 0.133
Due to SAEs 34 (0.32) 38 (0.32) 0.899
Due to drug-related* SAEs 6 (0.06) 7 (0.06) 0.866
Laboratory Values, m ⁄ n (%)
ALT‡ 3 · ULN, consecutive 31 ⁄ 10,341 (0.30) 50 ⁄ 11,512 (0.43) 0.084
AST‡ 3 · ULN, consecutive 23 ⁄ 10,342 (0.22) 30 ⁄ 11,512 (0.26) 0.525
ALT or AST‡ 3 · ULN, consecutive 36 ⁄ 10,342 (0.35) 64 ⁄ 11,512 (0.56) 0.017
CK‡ 10 · ULN 13 ⁄ 10,342 (0.13) 9 ⁄ 11,514 (0.08) 0.350
Myopathy! 4 ⁄ 10,342 (0.04) 3 ⁄ 11,512 (0.03) 0.67
Rhabdomyolysis" 0 ⁄ 10,342 (0.00) 0 ⁄ 11,512 (0.00) N ⁄ A
Specific AE groups, n (%) (n = 10,505) (n = 11,705)
Hepatitis-related§ 8 (0.08) 5 (0.04) 0.359
Gallbladder-related– 10 (0.10) 14 (0.12) 0.522
Gastrointestinal-related** 792 (7.54) 832 (7.11) 0.112
Allergic reaction or rash!! 139 (1.32) 185 (1.58) 0.254
Definitions of specific AE groups apply to all subgroup tables:
*Considered by the investigator to be possibly, probably or definitely related to study drug.
!Myopathy is defined as CK elevation > 10 · ULN with associated muscle symptoms with no other explanatory cause.
"Rhabdomyolysis is defined as myopathy with associated evidence of renal damage.
§In addition to review of the effects of ezetimibe + statin on laboratory parameters associated with liver function, ‘‘hepatitis-related’’
clinical AE terms (preferred MedDRA terms) were pre-identified for collective review, and included cholestasis, hepatitis, hepatic lesion,
hepatomegaly, hepatic cyst, hepatitis cholestatic.
–For gallbladder-related clinical AEs the preferred terms (preferred MedDRA terms) were pre-identified for collective review, including
bile duct obstruction, biliary colic, cholangitis, cholecystitis, cholecystitis chronic, cholelithiasis, and gallbladder disorder.
**For gastrointestinal-related clinical AEs, the preferred terms (preferred MedDRA terms) were pre-identified for collective review, and
included abdominal discomfort, abdominal distension, abdominal pain, abdominal tenderness, colitis, colonic polyp, constipation, dental
caries, dental discomfort, diarrhoea, diverticulum, duodenitis, dyspepsiea, dysphagia, erosive duodenitis, faeces discolored, flatulence,
food poisoning, gastritis, gastroesophageal reflux disease, gingival pain, haemorrhoids, hiatus hernia, nausea, oesophageal stenosis,
rectal haemorrhage, tooth loss, toothache,and vomiting.
!!For allergic reaction or rash the preferred terms (preferred MedDRA terms) were pre-identified for collective review, and included
analphylaxis, angioedema, dermatitis, dermagraphism, drug hypersensitivity, eczema, eosinophilia, erythema, face oedema, hypersensi-
tivity, palmar erythema, periorbital oedema, photodermatosis, photosensitivity, pigmentation disorder, priuritus, rash, rosacea, skin dis-
order, skin exfoliation, skin hyperpigmentation, skin inflammation, skin lesion, subcutaneious nodule, systemic lupus erythematosus
rash, and urticaria.
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with men, and a greater proportion of women had
metabolic syndrome compared with men. Compared
with older subjects (‡ 65 years), younger subjects
(< 65 years) had a higher proportion of non-Cauca-
sians and a higher proportion of subjects that were
treated with first-line therapy. The older group
included a higher proportion of subjects with CHD,
diabetes mellitus, and metabolic syndrome compared
with the younger age group. Compared with the
White and Other subgroups, Black subjects had a
higher proportion of females and subjects treated
with first-line therapy. Blacks had the lowest propor-
tion of subjects with CHD, while Whites had the
lowest proportion of subjects with diabetes mellitus
and metabolic syndrome. When comparing first-line
with second-line studies, subjects that were treated
with second-line therapy tended to be older by
approximately 4.5 years, and included a higher pro-
portion of males, subjects with CHD, and subjects
with diabetes mellitus, but included a smaller pro-
portion of subjects with metabolic syndrome and
non-Caucasians. Although mean BMI was similar
between all subgroups, women, subjects ‡ 65 years,
Black subjects and subjects treated first-line had
higher proportions with BMI ‡ 30 kg ⁄m2.
Safety results
In the full cohort (Table 3), the only significant dif-
ference between treatments was in consecutive AST
or ALT elevations ‡ 3 · ULN. Although the inci-
dence (0.35% vs. 0.56%, statin vs. statin ⁄ ezetimibe)
was small in both treatment groups, there were sig-
nificantly more reports of elevations in subjects trea-
ted with ezetimibe ⁄ statin therapy (p = 0.017).
Otherwise, both treatments had generally similar tol-
erability and safety profiles (i.e., there were no
between-treatment differences in the proportion of
subjects reporting ‡ 1 AEs, drug-related AEs, serious
AEs, serious drug-related AEs, discontinuations due
to AEs, or CK elevations ‡ 10 · ULN). There was no
difference in the incidence of myopathy, which was
small in both treatment groups (0.03%–0.04%), and
there were no cases of rhabdomyolysis in any of the
studies. A total of 12 deaths were reported during
Table 4 Summary of safety data in men and women
Male Female p-value for effects
Statin Statin ⁄ EZ Statin Statin ⁄ EZ Treatment Sex
Sex by treatment
interaction
AE summary, n (%) (n = 5380) (n = 6129) (n = 5137) (n = 5585)
‡ 1 AE 1537 (28.57) 1779 (29.03) 1918 (37.34) 1938 (34.70) – < 0.001 0.014
Drug-related* AE 349 (6.49) 456 (7.44) 484 (9.42) 505 (9.04) 0.017 < 0.001 –
Serious AEs (SAEs) 74 (1.38) 107 (1.75) 71 (1.38) 80 (1.43) – – –
Drug-related* SAEs 2 (0.04) 8 (0.13) 4 (0.08) 5 (0.09) – – –
Death 4 (0.07) 3 (0.05) 1 (0.02) 4 (0.07) – – –
Discontinuations
Due to an AE 91 (1.69) 105 (1.71) 128 (2.49) 158 (2.83) – 0.016 –
Due to drug-related* AE 49 (0.91) 69 (1.13) 87 (1.69) 108 (1.93) – 0.002 –
Due to SAEs 18 (0.33) 23 (0.38) 16 (0.31) 15 (0.27) – – –
Due to drug-related* SAEs 2 (0.04) 4 (0.07) 4 (0.08) 3 (0.05) – – –
Laboratory values, m ⁄ n (%)
ALT‡ 3 · ULN, consecutive 15 ⁄ 5289 (0.28) 34 ⁄ 6031 (0.56) 16 ⁄ 5052 (0.32) 16 ⁄ 5481 (0.29) 0.018 – –
AST‡ 3 · ULN, consecutive 7 ⁄ 5290 (0.13) 16 ⁄ 6031 (0.27) 16 ⁄ 5052 (0.32) 14 ⁄ 5481 (0.26) – 0.049 –
ALT or AST‡ 3 · ULN,
consecutive
17 ⁄ 5290 (0.32) 41 ⁄ 6031 (0.68) 19 ⁄ 5052 (0.38) 23 ⁄ 5481 (0.42) 0.005 – –
CK‡ 10 · ULN 9 ⁄ 5290 (0.17) 7 ⁄ 6033 (0.12) 4 ⁄ 5052 (0.08) 2 ⁄ 5481 (0.04) – – –
Myopathy 2 ⁄ 5290 (0.04) 2 ⁄ 6033 (0.03) 2 ⁄ 5052 (0.04) 1 ⁄ 5481 (0.02) – – –
Rhabdomyolysis 0 ⁄ 5290 (0.00) 0 ⁄ 6033 (0.00) 0 ⁄ 5052 (0.00) 0 ⁄ 5481 (0.00) – – –
Specific AE groups!, n (%) (n = 5372) (n = 6124) (n = 5133) (n = 5581)
Hepatitis-related 4 (0.07) 4 (0.07) 4 (0.08) 1 (0.02) – – –
Gallbladder-related 3 (0.06) 6 (0.10) 7 (0.14) 8 (0.14) – – –
Gastrointestinal-related 324 (6.03) 370 (6.04) 468 (9.12) 462 (8.28) – < .001 –
Allergic reaction or rash 50 (0.93) 79 (1.29) 89 (1.73) 106 (1.90) – < .001 –
*Considered by the investigator to be possibly, probably or definitely related to study drug.
!Definitions of specific AE groups are the same as those in Table 3.
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the course of all 27 studies and none of the deaths
were attributed to treatment. The causes of the five
deaths in the statin group were due to head injury
after a fall, chronic obstructive pulmonary disease,
sudden cardiac death, mixed drug ingestion, and
myocardial infarction. The causes of the seven deaths
in the statin ⁄ ezetimibe group were suicide, two
deaths due to head injury, hypotension ⁄ respiratory
failure, cardiac arrest, stroke, and spontaneous abor-
tion leading to fetal death. The results of the sensitiv-
ity analysis were consistent with the original logistic
regression model analysis, with statistically signifi-
cantly greater reports in consecutive AST or ALT ele-
vations ‡ 3 · ULN in ezetimibe ⁄ statin-treated
subjects compared with statin monotherapy-treated
subjects (p = 0.041).
Generally, higher AE rates were reported for
women regardless of treatment (Table 4). When com-
paring the sexes, women reported significantly more
AEs (i.e., ‡ 1 AE), drug-related AEs, discontinuations
due to AEs, discontinuations due to drug-related AEs,
gastrointestinal-related AEs, allergic reaction- or rash-
related AEs and AST elevations ‡ 3 · ULN than men.
Among men, a significantly greater proportion trea-
ted with the combination of statin ⁄ ezetimibe reported
AST or ALT elevations ‡ 3 · ULN, and ALT eleva-
tions ‡ 3 · ULN than those treated with statin alone.
There were no significant differences between men
and women in the occurrence of myopathy, which
was small in both sexes.
Generally similar rates of AEs were reported
between the age groups (Table 5), although signifi-
cantly more reports of drug-related serious AEs
occurred in the statin ⁄ ezetimibe group and this was
driven mainly by reports in subjects < 65 years. Also
among subjects < 65 years of age, those being treated
with the combination statin ⁄ ezetimibe reported sig-
nificantly more discontinuations due to drug-related
serious AEs, and ALT and ⁄or AST elevations
‡ 3 · ULN compared with subjects ‡ 65 years trea-
ted with statin alone. Significantly more subjects
‡ 65 years reported serious AEs and discontinued
due to serious AEs compared with subjects
< 65 years, whereas significantly more subjects
Table 5 Summary of safety data by age group
< 65 years ‡ 65 years p-value for effects
Statin Statin ⁄ EZ Statin Statin ⁄ EZ Treatment Age
Age by
treatment
interaction
AE summary, n (%) (n = 6816) (n = 7406) (n = 3701) (n = 4308)
‡ 1 AE 2368 (34.74) 2426 (32.76) 1087 (29.37) 1291 (29.97) – – –
Drug-related* AE 577 (8.47) 638 (8.61) 256 (6.92) 323 (7.50) – – –
Serious AEs (SAEs) 74 (1.09) 93 (1.26) 71 (1.92) 94 (2.18) – < 0.001 –
Drug-related* SAEs 3 (0.04) 13 (0.18) 3 (0.08) 0 (0.00) 0.014 – 0.003
Death 4 (0.06) 3 (0.04) 1 (0.03) 4 (0.09) – – –
Discontinuations
Due to an AE 137 (2.01) 160 (2.16) 82 (2.22) 103 (2.39) – – –
Due to drug-related* AE 90 (1.32) 114 (1.54) 46 (1.24) 63 (1.46) – – –
Due to SAEs 17 (0.25) 18 (0.24) 17 (0.46) 20 (0.46) – 0.035 –
Due to drug-related* SAEs 3 (0.04) 7 (0.09) 3 (0.08) 0 (0.00) – – 0.014
Laboratory values, m ⁄ n (%)
ALT‡ 3 · ULN, consecutive 21 ⁄ 6698 (0.31) 44 ⁄ 7270 (0.61) 10 ⁄ 3643 (0.27) 6 ⁄ 4242 (0.14) 0.009 – 0.020
AST‡ 3 · ULN, consecutive 12 ⁄ 6699 (0.18) 24 ⁄ 7270 (0.33) 11 ⁄ 3643 (0.30) 6 ⁄ 4242 (0.14) – – 0.023
ALT or AST‡ 3 · ULN, consecutive 23 ⁄ 6699 (0.34) 56 ⁄ 7270 (0.77) 13 ⁄ 3643 (0.36) 8 ⁄ 4242 (0.19) 0.001 – 0.004
CK‡ 10 · ULN 12 ⁄ 6699 (0.18) 7 ⁄ 7272 (0.10) 1 ⁄ 3643 (0.03) 2 ⁄ 4242 (0.05) – 0.049 –
Myopathy 3 ⁄ 6699 (0.03) 2 ⁄ 7272 (0.02) 1 ⁄ 3643 (0.03) 1 ⁄ 4242 (0.02) – – –
Rhabdomyolysis 0 ⁄ 6699 (0.00) 0 ⁄ 7272 (0.00) 0 ⁄ 3643 (0.00) 0 ⁄ 4242 (0.00) – – –
Specific AE groups!, n (%) (n = 6809) (n = 7401) (n = 3696) (n = 4304)
Hepatitis-related 6 (0.09) 3 (0.04) 2 (0.05) 2 (0.05) – – –
Gallbladder-related 7 (0.10) 5 (0.07) 3 (0.08) 9 (0.21) – – –
Gastrointestinal-related 543 (7.97) 542 (7.32) 249 (6.74) 290 (6.74) – – –
Allergic reaction or rash 102 (1.50) 124 (1.68) 37 (1.00) 61 (1.42) – – –
*Considered by the investigator to be possibly, probably or definitely related to study drug.
!Definitions of specific AE groups are the same as those in Table 3.
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< 65 years reported CK elevations ‡ 10 · ULN com-
pared with subjects ‡ 65 years. There were no signifi-
cant differences between subjects < 65 years and
‡ 65 years in the occurrence of myopathy regardless
of treatment, which was small in both age groups.
Likewise, there were generally similar rates of AEs
reported between race subgroups (Table 6), with a
few exceptions. Subjects in the ‘Other’ subgroup
reported significantly fewer AEs (i.e., ‡ 1 AE) and
drug-related AEs compared with Black or White sub-
jects. Among White subjects, significantly more who
were treated with the combinations of statin ⁄ ezetim-
ibe experienced AST or ALT elevations ‡ 3 · ULN
compared with White subjects treated with statin
monotherapy, although the incidence was low. There
was no other difference between treatments in the
Black or Other subgroups. Finally, although the pro-
portions were very small (< 1%) in both treatment
groups in all three race subgroups overall, among
Black subjects, there was a significantly higher
proportion of CK elevations ‡ 10 · ULN treated
with statin monotherapy compared with statin ⁄ eze-
timibe combination (0.69% vs. 0.0%). There were no
significant differences between race groups in the
occurrence of myopathy, which was low in all three
groups.
There was a significant effect of treatment, as well
as a first-line ⁄ second-line by treatment interaction
on serious AEs, with more reports in the combina-
tion of statin ⁄ ezetimibe vs. statin monotherapy in
subjects who were taking ongoing statin at study
entry (subjects treated second-line) (Table 7). There
was also a significant effect of treatment on allergic
reaction or rash AEs, with more reports in the com-
bination of statin ⁄ ezetimibe vs. statin monotherapy
in both first-line and subjects treated second-line
(Table 7). A significantly greater proportion of sub-
jects who were treated first-line reported ‡ 1 AE,
drug-related AEs, serious AEs, potentially hepatitis-
related AEs, gastrointestinal-related AEs, allergic
Table 6 Summary of safety data by race groups
White Black Other p-value for effects
Statin Statin ⁄ EZ Statin Statin ⁄ EZ Statin Statin ⁄ EZ Treatment Race
Race by
treatment
interaction
AE summary, n (%) (n = 8837) (n = 9888) (n = 738) (n = 830) (n = 942) (n = 996)
‡ 1 AE 2911 (32.94) 3170 (32.06) 256 (34.69) 279 (33.61) 288 (30.57) 268 (26.91) – 0.048 –
Drug-related* AE 714 (8.08) 821 (8.30) 65 (8.81) 72 (8.67) 54 (5.73) 68 (6.83) – 0.037 –
Serious AEs (SAEs) 127 (1.44) 165 (1.67) 10 (1.36) 12 (1.45) 8 (0.85) 10 (1.00) – – –
Drug-related* SAEs 5 (0.06) 9 (0.09) 1 (0.14) 1 (0.12) 0 (0.00) 3 (0.30) – – –
Death 5 (0.06) 6 (0.06) 0 (0.00) 0 (0.00) 0 (0.00) 1 (0.10) – – –
Discontinuations – –
Due to an AE 188 (2.13) 232 (2.35) 16 (2.17) 13 (1.57) 15 (1.59) 18 (1.81) – – –
Due to drug-related* AE 118 (1.34) 158 (1.60) 9 (1.22) 7 (0.84) 9 (0.96) 12 (1.20) – – –
Due to SAEs 30 (0.34) 30 (0.30) 3 (0.41) 3 (0.36) 1 (0.11) 5 (0.50) – – –
Due to drug-related* SAEs 5 (0.06) 4 (0.04) 1 (0.14) 0 (0.00) 0 (0.00) 3 (0.30) – – –
Laboratory values, m ⁄ n (%)
ALT‡ 3 · ULN, consecutive 24 ⁄ 8701 (0.28) 41 ⁄ 9726 (0.42) 2 ⁄ 727 (0.28) 3 ⁄ 810 (0.37) 5 ⁄ 913 (0.55) 6 ⁄ 976 (0.61) – – –
AST‡ 3 · ULN, consecutive 20 ⁄ 8702 (0.23) 24 ⁄ 9726 (0.25) 0 ⁄ 727 (0.00) 0 ⁄ 810 (0.00) 3 ⁄ 913 (0.33) 6 ⁄ 976 (0.61) – 0.004 –
ALT or AST‡ 3 · ULN,
consecutive
29 ⁄ 8702 (0.33) 53 ⁄ 9726 (0.54) 2 ⁄ 727 (0.28) 3 ⁄ 810 (0.37) 5 ⁄ 913 (0.55) 8 ⁄ 976 (0.82) 0.024 – –
CK‡ 10 · ULN 7 ⁄ 8702 (0.08) 6 ⁄ 9728 (0.06) 5 ⁄ 727 (0.69) 0 ⁄ 810 (0.00) 1 ⁄ 913 (0.11) 3 ⁄ 976 (0.31) – 0.008 0.023
Myopathy 2 ⁄ 8702 (0.02) 1 ⁄ 9728 (0.01) 1 ⁄ 727 (0.14) 1 ⁄ 810 (0.12) 1 ⁄ 913 (0.11) 1 ⁄ 976 (0.10) – – –
Rhabdomyolysis 0 ⁄ 8702 (0.00) 0 ⁄ 9728 (0.00) 0 ⁄ 727 (0.00) 0 ⁄ 810 (0.00) 0 ⁄ 913 (0.00) 3 ⁄ 976 (0.31) – – –
Specific AE groups!, n (%) (n = 8842) (n = 9893) (n = 737) (n = 828) (n = 926) (n = 983)
Hepatitis-related 8 (0.09) 4 (0.04) 0 (0.00) 0 (0.00) 0 (0.00) 1 (0.10) – – –
Gallbladder-related 10 (0.11) 13 (0.13) 0 (0.00) 0 (0.00) 0 (0.00) 1 (0.10) – – –
Gastrointestinal-related 675 (7.63) 720 (7.28) 48 (6.51) 59 (7.13) 69 (7.45) 53 (5.39) – – –
Allergic reaction or rash 114 (1.29) 160 (1.62) 8 (1.09) 14 (1.69) 17 (1.84) 11 (1.12) – – –
*Considered by the investigator to be possibly, probably or definitely related to study drug.
!Definitions of specific AE groups are the same as those in Table 3.
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reaction or rash AEs, and CK elevations ‡ 10 · ULN
compared with subjects treated second-line in both
treatment groups (Table 7). There was no significant
difference between subjects treated first-line com-
pared with second-line in the occurrence of myopa-
thy, which was low overall.
Discussion
The efficacy and safety profiles of ezetimibe, statins,
and the combination of ezetimibe with various doses
of statins have been well-established by numerous
clinical trials in the general population. The accumu-
lation of study data into a large database from 27
studies conducted over several years provided the
opportunity to assess the safety and tolerability pro-
files of ezetimibe combined with statins in the overall
population and in population subgroups with
increased statistical power. The results of this pooled
analysis confirm that the overall safety and tolerability
profiles of ezetimibe added to a statin are generally
comparable to statin monotherapy for up to
24 weeks. Irrespective of treatment group, generally
higher rates of AEs were reported in women com-
pared with men, and generally similar rates of AEs
were reported between races and between age groups.
More AEs were reported by subjects in first-line stud-
ies than subjects in second-line studies. The occur-
rence of myopathy was low and did not differ
between treatments or any of the subgroups studied.
Although the incidence was low, elevations in liver
enzymes were observed more often with ezetim-
ibe ⁄ statin combination treatment compared with sta-
tin monotherapy in the overall population and in
most subgroups studied. These rates were consistent
with the incidence reported in the prescribing infor-
mation for statin monotherapy (0.7%–1.9%) and
ezetimibe combined with simvastatin (Vytorin;
1.7%) (13,14) Similarly, in an efficacy and safety
analysis conducted in the same database as this
Table 7. Summary of safety data in patients grouped by those receiving first-line treatment or second-line treatment
First-line Second-line p-value for effects
Statin Statin ⁄ EZ Statin Statin ⁄ EZ Treatment
First ⁄ second
line
First- ⁄ second-line
by treatment
interaction
AE summary, n (%) (n = 6694) (n = 6664) (n = 3823) (n = 5050)
‡ 1 AE 2553 (38.14) 2510 (37.67) 902 (23.59) 1207 (29.90) – < 0.001 –
Drug-related* AE 591 (8.83) 636 (9.54) 242 (6.33) 325 (6.44) – < 0.001 –
Serious AEs (SAEs) 95 (1.42) 91 (1.37) 50 (1.31) 96 (1.90) 0.016 – 0.035
Drug-related* SAEs 4 (0.06) 9 (0.14) 2 (0.05) 4 (0.08) – – –
Death 4 (0.06) 3 (0.04) 2 (0.05) 3 (0.06) – – –
Discontinuations
Due to an AE 150 (2.24) 170 (2.55) 69 (1.80) 93 (1.84) – – –
Due to drug-related* AE 91 (1.36) 116 (1.74) 45 (1.18) 61 (1.21) – – –
Due to SAEs 25 (0.37) 25 (0.38) 9 (0.24) 13 (0.26) – – –
Due to drug-related* SAEs 4 (0.06) 6 (0.09) 2 (0.05) 1 (0.02) – – –
Laboratory values, m ⁄ n (%)
ALT‡ 3 · ULN, consecutive 22 ⁄ 6586 (0.33) 32 ⁄ 6557 (0.49) 9 ⁄ 3755 (0.24) 18 ⁄ 4955 (0.36) – – –
AST‡ 3 · ULN, consecutive 18 ⁄ 6587 (0.27) 17 ⁄ 6557 (0.26) 5 ⁄ 3755 (0.13) 13 ⁄ 4955 (0.26) – – –
ALT or AST‡ 3 · ULN,
consecutive
26 ⁄ 6587 (0.39) 41 ⁄ 6557 (0.63) 10 ⁄ 3755 (0.27) 23 ⁄ 4955 (0.46) – – –
CK‡ 10 · ULN 12 ⁄ 6587 (0.18) 7 ⁄ 6558 (0.11) 1 ⁄ 3755 (0.03) 2 ⁄ 4956 (0.04) – 0.016 –
Myopathy 3 ⁄ 6587 (0.05) 3 ⁄ 6558 (0.05) 1 ⁄ 3755 (0.03) 0 ⁄ 4956 (0.00) – – –
Rhabdomyolysis 0 ⁄ 6587 (0.00) 0 ⁄ 6558 (0.00) 0 ⁄ 3755 (0.00) N ⁄ A – – –
Specific AE groups!, n (%) (n = 6684) (n = 6662) (n = 3821) (n = 5043)
Hepatitis-related 8 (0.12) 5 (0.08) 0 (0.00) 0 (0.00) – < 0.001 –
Gallbladder-related 8 (0.12) 7 (0.11) 2 (0.05) 7 (0.14) – – –
Gastrointestinal-related 618 (9.25) 572 (8.59) 174 (4.55) 260 (5.16) – < 0.001 0.010
Allergic reaction or rash 122 (1.83) 140 (2.10) 17 (0.44) 45 (0.89) 0.030 < 0.001 0.044
*Considered by the investigator to be possibly, probably or definitely related to study drug.
!Definitions of specific AE groups are the same as those in Table 3.
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pooled analysis, but in both subgroups of patients
with and without diabetes, consecutive or presumed
consecutive elevations > 3 · ULN in liver enzymes
were also noted somewhat more frequently in sub-
jects receiving ezetimibe ⁄ statin combination com-
pared with statin monotherapy (12).
There was a statistically significant treatment effect
reported for CK elevations ‡ 10 · ULN among Black
subjects, with increases observed significantly more
often with statin monotherapy vs. the combination
treatment. However, these elevations resulted in
myopathy in only two cases, one in each treatment
group. Given the small number of events, this was
likely a chance imbalance. No such racial imbalances
in the incidence of myopathy have been identified in
the literature. Additional safety studies with an even
greater number of Black subjects and prespecified
endpoints are needed to produce conclusive evidence
about muscle-related safety with statin and ⁄or eze-
timibe-plus-statin treatment.
Interestingly, although there was no treatment
effect among subjects grouped by age, there was an
age effect with more subjects in the younger age
group reporting CK elevations ‡ 10 · ULN com-
pared with older subjects. Based on what is known
about the increased risk of myopathy, (which
involves CK elevations) in older subjects, one would
predict that more subjects in the older age group
would have CK elevations ‡ 10 · ULN compared
with younger subjects (5,15). One explanation may
be that there was a much higher proportion of sub-
jects < 65 years included in the first-line studies
compared with second-line studies, which also
reported a significantly greater effect on CK eleva-
tions ‡ 10 · ULN, and therefore many older subjects
included in this pooled analysis may have been
screened out for adverse effects or risk for CK eleva-
tions. Indeed, screening out for tolerability issues
may explain why subjects treated second-line
reported significantly fewer clinical and laboratory
AEs compared with subjects treated first-line. In the
second-line studies, subjects who experienced AEs
most likely did not continue to randomization.
There were some differences between the sexes,
with women reporting significantly more clinical AEs
and discontinued treatment due to AEs compared
with men, regardless of treatment. In addition to
potential tolerability issues in women, liver enzyme
elevations were more common with the combination
treatment than with statin monotherapy in men, but
not in women. More than 40% of the men included
in these trials were diagnosed with CHD at baseline
compared with 26% among women. It is possible
that men were taking more concomitant medica-
tions, which affected drug metabolism and
contributed to elevations in liver enzymes. An evalu-
ation of ALT and CK elevation in an ambulatory
care setting (N = 4958) found that significant eleva-
tions in either ALT or CK during ezetimibe treat-
ment is usually associated with concomitant
medications and that rates of ALT and ⁄or CK eleva-
tions were similar to that of placebo (16).
Limitations
These trials were short-term (6–24 weeks, mean
duration of follow-up = 9 weeks), and therefore
could not assess long-term safety and tolerability.
However, long-term trials have also documented the
safety of ezetimibe combined with statin therapy
(17–20). In addition, many patients had been receiv-
ing statins prior to enrolling in the trials, and this
likely would influence the on-study AE profile. Fur-
ther studies assessing tolerability in patients without
previous statin treatment may help clarify whether
specific subgroups are more likely to experience par-
ticular AEs. Although rosuvastatin was assessed as a
monotherapy, there were no treatment arms that
included the combination of ezetimibe with rosuvast-
atin included in this database. However, clinical
experience suggests that the safety and tolerability
profiles of that combination would be generally simi-
lar to other statin ⁄ ezetimibe combinations (21–23).
Conclusion
In conclusion, ezetimibe added to a statin and statin
monotherapy both provide generally safe and well-
tolerated therapeutic options for dyslipidemia. These
results describe the safety profiles over 6–24 weeks of
widely used lipid-lowering therapies and encourage
appropriate and judicious use of lipid-altering ther-
apy in certain subpopulations. Individual monitoring
in patients with risk factors, such as older females or
those taking concomitant medications is warranted.
Finally, the results of this analysis confirm the results
of a previous systematic review concluding that the
addition of ezetimibe to a statin appears unlikely to
increase the incidence of myopathy (6).
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